November 2017

LGC Genomics strengthens leadership team to support launch of new NGS business unit

LGC, the international life sciences company, today announced that it has appointed Emma Millican as Global NGS Business Unit Manager and Dr. Harold Swerdlow as Head of NGS Technology Development for their recently established Next Generation Sequencing Business Unit as part of their expanding Genomics division. These appointments further strengthen LGC’s in-house expertise to help drive the development of its Next Generation Sequencing (NGS) products and services.

Emma Millican has a wealth of experience in commercial and operational management within the Molecular Biology field. Prior to joining LGC Genomics Emma was the Director of Scientific Operations at the Wellcome Trust Sanger Institute.

Harold Swerdlow joins LGC in December, bringing a wealth of NGS experience, with previous notable appointments at the New York Genome Center, the Wellcome Trust Sanger Institute, Dolomite and Solexa Ltd. (now Illumina, Inc.), where he was one of the inventors of Next-Generation Sequencing.

Emma Millican said, “It’s exciting to be able to apply my commercial and operational experience I have gained in setting up and managing large-scale NGS operations to oversee the NGS activity in LGC Genomics."

Harold Swerdlow said, "I am absolutely thrilled to be joining the NGS group at LGC, one of the world's leaders in genetic analysis. Being part of this nascent effort in genomics is an exciting step forward for me and I look forward to working with the excellent team that has been assembled so far and contributing to building the NGS portfolio even further."

Commenting on the appointments, Mark Dearden, VP Strategy and Marketing, LGC Genomics said, “I am very pleased that Emma and Harold are joining LGC. Both bring world-class experience in the Next Generation Sequencing market and will help drive the next phase of growth for our NGS business unit that is delivering our strategy to develop mission critical products and services into both Human Healthcare as well as Agrigenomics market sectors.”